Skip to main content
. Author manuscript; available in PMC: 2019 Jul 6.
Published in final edited form as: Eur Respir J. 2019 Apr 11;53(4):1801641. doi: 10.1183/13993003.01641-2018

Figure 1. Rate of pulmonary disease progression of Interstitial Lung Disease patients as measured by the mean change in FVC.

Figure 1.

Estimated change of Forced Vital Capacity (FVC) percent predicted per year for patients with Idiopathic Pulmonary Fibrosis (IPF), Interstitial Pneumonia with Autoimmune Features (IPAF), and Connective Tissue Disease-associated Interstitial Lung Disease (CTD-ILD) stratified by an age-adjusted blood leukocyte telomere length less than or greater than 10th percentile (A), by the presence of the MUC5B rs35705950 minor allele (GT/TT) (B), and by the presence of TOLLIP rs5743890 minor allele (AG/GG) (C). This analysis was limited to the subset of patients for which there were at least 3 spirometry measurements spanning over at least 90 days. Significant with Bonferroni correction for multiple testing with three predictors (LTL, MUC5B, TOLLIP) per diagnosis; alpha level of 0.017 per test (0.05/3)